Subject(s)
Abscess , Diagnostic Errors , Kidney Neoplasms , Humans , Kidney Neoplasms/diagnosis , Kidney Neoplasms/surgery , Abscess/diagnosis , Male , Carcinoma, Renal Cell/diagnosis , Carcinoma, Renal Cell/surgery , Middle Aged , Kidney Diseases/diagnosis , Female , Tomography, X-Ray Computed , Neoplasm InvasivenessSubject(s)
Headache/diagnosis , Headache/pathology , Neuroschistosomiasis/diagnosis , Neuroschistosomiasis/pathology , Schistosomiasis japonica/diagnosis , Schistosomiasis japonica/pathology , Brain/diagnostic imaging , Brain/pathology , Brain/surgery , Diagnosis, Differential , Headache/etiology , Humans , Male , Middle Aged , Neuroschistosomiasis/surgery , Schistosomiasis japonica/surgeryABSTRACT
Phosphoglycerate kinase 1 (PGK1) has been demonstrated to be involved in radioresistance. The present study was designed to investigate the effect of PGK1 on the radioresistance in vivo. U251 glioma cells were transfected with the short hairpin RNA (shRNA)-PGK1 and pcDNA3.1-PGK1 using Lipofectamine 2000. The radiosensitivity of U251 xenografts was observed by tumor growth curve following radiotherapy. Quantitative PCR, western blot analysis and immunohistochemistry were performed to evaluate PGK1 expression in the xenografts from the different tumor models. The expression of PGK1 was maximally inhibited in response to shRNA4 at 24 h after the transfection in vitro. Tumor growth of the U251 xenografts was significantly inhibited following treatment with shRNA-PGK1 and radiotherapy. The expression of PGK1 in vivo at the mRNA and protein levels was downregulated by the treatment of shRNA1 when compared to levels following treatment with shNC and PBS after radiotherapy. The results showed that suppression of PGK1 enhanced the radiosensitivity of U251 xenografts and suggest that PGK1 may serve as a useful target in the treatment of radioresistant glioma.
Subject(s)
Glioma/genetics , Phosphoglycerate Kinase/genetics , Radiation Tolerance/genetics , Animals , Cell Line, Tumor , Cell Movement/radiation effects , Cell Survival/radiation effects , Down-Regulation , Gene Knockdown Techniques , Glioma/radiotherapy , Humans , Mice , Mice, Nude , RNA, Small Interfering , Radiation , Xenograft Model Antitumor AssaysABSTRACT
Phosphoglycerate kinase 1 (PGK1) has been found to be increased in radioresistant astrocytomas. The present study was designed to investigate the potential role of PGK1 in the radioresistance in U251 human cells. Quantitative PCR and western blot analysis were performed to evaluate PGK1 expression for mRNA levels and protein levels, respectively. The short hairpin RNA (shRNA)-PGK1 and the high expression plasmids were transfected to radioresistant U251 cells (RR-U251 cells) or normal U251 cells using lipofectamine™ 2000. The cell viability was determined by MTT assay. The wound-healing assay (WHA) was used to evaluate cell migration ability. Cell invasion abilities were examined using a Transwell culture chamber system. Our results showed that the expression of PGK1 was significantly increased in RR-U251 cells compared to normal U251 cells. Following irradiation, the cell viability as well as the migration and invasion ability were significantly higher in RR-U251 cells compared with normal U251 cells. Downregulating PGK1 using shRNA induced a significantly downregulated cell viability and decreased migration and invasion ability, and overexpression of PGK1 contributed to upregulated cell viability and increased migration and invasion ability, both in RR-U251 cells and normal U251 cells. These findings suggest that PGK1 could promote radioresistance in U251 human cells.
Subject(s)
Brain Neoplasms/radiotherapy , Glioma/radiotherapy , Phosphoglycerate Kinase/genetics , Radiation Tolerance/genetics , Brain Neoplasms/genetics , Cell Line, Tumor , Cell Movement/genetics , Cell Proliferation , Cell Survival/radiation effects , Gene Expression Regulation, Neoplastic , Glioma/genetics , Humans , Neoplasm Invasiveness/genetics , Phosphoglycerate Kinase/biosynthesis , RNA Interference , RNA, Small InterferingABSTRACT
The purpose of this study is to evaluate the steaming-induced chemical transformation of red ginseng manufactured from fresh ginseng by means of simultaneous quantitative and qualitative analyses with a combinative high-performance liquid chromatography-electrospray tandem mass spectrometry (HPLC-ESI-MS/MS(n)) technique. Thirty-six ginsenosides were identified in red ginseng and white ginseng by comparing the mass spectrum and/or matching the empirical molecular formula with that of known published compounds, and 11 of them were determined to be newly generated during the red ginseng preparatory process. The mechanisms involved were further deduced to be hydrolysis, dehydration, isomerization, and decarboxylation at C-20, and hydrolysis also occurs at C-3 or C-6 of the original ginsenosides through the mimic process of steaming and heating in laboratory. The multicomponent quantification fingerprint of ginseng was also established by HPLC-UV method, and the contents of 12 ginsenosides in red and white ginsengs from different sources were determined simultaneously. The ratio of the total content of determined malonyl ginsenosides to the corresponding neutral ginsenosides (T(m-PPD)/T(PPD)) in white ginseng ranged from 0.46 to 0.62 and from 0 to 0.19 in red ginseng. The validated method is expected to provide an effective approach to standardize the processing procedures of ginseng products and regulate the usage of ginseng in Traditional Chinese Medical prescription.
Subject(s)
Chromatography, High Pressure Liquid/methods , Ginsenosides/analysis , Panax/chemistry , Plant Extracts/isolation & purification , Ginsenosides/chemistry , Molecular Structure , Plant Extracts/chemistry , Reference Standards , Steam , Tandem Mass Spectrometry/methods , Technology, Pharmaceutical/standardsABSTRACT
BACKGROUND: Shuanglong formula (SLF), a Chinese medicine composed of panax ginseng and salvia miltiorrhiza exhibited significant effect in the treatment of myocardial infarction (MI) in clinical. Because of the complex nature and lack of stringent quality control, it's difficult to explain the action mechanism of SLF. METHOD: In this study, we present a "system to system" (S2S) mode. Based on this mode, SLF was simplified successively through bioactivity-guided screening to achieve an optimized minimal phytochemical composition (new formula NSLF6) while maintaining its curative effect for MI. RESULTS: Pharmacological test combining with the study of systems biology show that NSLF6 has activity for treatment MI through synergistic therapeutic efficacies between total ginsenosides and total salvianolic acids via promoting cardiac cell regeneration and myocardial angiogenesis, antagonistic myocardial cell oxidative damage. CONCLUSIONS: The present S2S mode may be an effective way for the discovery of new composite drugs from traditional medicines.
